The approval makes Wegovy the only GLP-1 therapy cleared to treat adults with metabolic dysfunction-associated ...

CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on Novo Nordisk, what new FDA approval on its ...

Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s ...

Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other ...

The weight-loss drug Wegovy just got FDA approval to treat a common and serious liver condition known as MASH (Metabolic ...

The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on ...

The FDA has approved Wegovy for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis ...

Novo Nordisk’s GLP-1 drug Wegovy expanded its label to include the metabolic disorder known as MASH. Analysts say there’s ...

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...

Novo Nordisk's Wegovy has received accelerated approval for use in patients with metabolic dysfunction-associated ...

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

Novo Nordisk (NYSE:NVO) is one of the Most Profitable Large Cap Stocks to Buy According to Analysts. On August 15, Novo ...